Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-20

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this pilot experimental medicine interventional study is to explore the degree of transferability of the gut microbiome and associated metabolomic changes in patients with non-alcoholic fatty liver disease (NAFLD) and fibrosis who receive faecal microbiota transplant (FMT). The main questions is aims to answer is:

* To what extent is the gut microbiome transferable from donor to recipient in patients with NAFLD with fibrosis who receive FMT?
* What are the dynamics of how the gut microbiome changes over time in these patients?
* To what degree does the recipient metabolome change in association with this?

Participants will receive up to three capsulised FMT preparations prepared from a donor selected rationally based upon their metabolomic characteristics. They will be asked to attend for serial clinical assessments (including FibroScan and MRE/ MRI-PDFF), and will also be asked to provide serial blood, urine and stool samples for assessment of microbiome and metabolome profiling.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease

NCT03635541

Non-Alcoholic Fatty Liver Disease

UNKNOWN

Gut Microbiota and Modulation of Liver Damage in NAFLD

NCT02158351

Simple Steatosis (SS) Non-alcoholic Steatohepatitis (NASH) Obesity

COMPLETED

Integrated Diagnostics for Early Diagnosis of Liver Disease

NCT04666402

Non-Alcoholic Fatty Liver Disease Non-alcoholic Steatohepatitis Alcoholic Liver Disease +1 more

RECRUITING

COVID19-FOIE National Observatory

NCT04375670

Liver Diseases COVID19

COMPLETED

Mitochondrial Metabolism and Hepatic Complications of Obesity

NCT03302481

Obesity

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Alcoholic Fatty Liver Disease Fecal Microbiota Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Human participants with NAFLD and fibrosis

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NAFLD patients

Patients receiving capsulised FMT

Group Type EXPERIMENTAL

Faecal microbiota transplant

Intervention Type OTHER

Capsulised faecal microbiota transplant prepared from rationally selected donor, based upon donor metabolomic charateristics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Faecal microbiota transplant

Capsulised faecal microbiota transplant prepared from rationally selected donor, based upon donor metabolomic charateristics

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18-75 years of age.
2. Previously-diagnosed NAFLD, with predicted fibrosis based upon non-invasive assessment with FibroScan (i.e. liver stiffness measurement (LSM) \> 8kPa).
3. Raised liver ALT (\> 30IU/l for men, \> 19IU/l for women) or AST (\> 37IU/l for men, \> 31IU/l for women) with negative non-invasive liver screen (including negative screen for viral hepatitis, autoimmune liver disease and metabolic liver disease, and normal echocardiogram within two years in the scenario where congestive hepatopathy may be considered).
4. Able to consent for themselves in English.

Exclusion Criteria

1. Severe or life-threatening food allergy.
2. Pregnant or lactating women; or women trying to conceive.
3. Patients with suspected or confirmed cirrhosis (as assessed by clinical, radiological or histological criteria).
4. Use of particular medications, including:

1. Systemic antibiotics within the six weeks prior to study enrolment.
2. Immunosuppression that may influence risks related to FMT (including - but not limited to: use of corticosteroids within eight weeks of intervention; use of cytotoxic chemotherapy; use of azathioprine, tacrolimus, mycophenolate mofetil and/or immunosuppressive biologic therapy, e.g. infliximab).
3. Use of GLP-1 agonists.
5. Patients not expected to survive the duration of the study's follow-up (six months).
6. Swallowing difficulties that may preclude safe use of FMT capsules, including oral-motor dyscoordination.
7. Alcohol consumption \> 20g/ day.
8. Any active cancer (including treatment within the past six months).
9. Active infection at the point of recruitment, including COVID-19 infection.
10. Prior receipt of a liver transplant.
11. BMI \< 23 in Asian potential participants and BMI \< 25 in Caucasians.
12. Advanced chronic kidney disease (eGFR \< 30 ml/min).
13. Chronic intestinal disease, including coeliac disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, and chronic diarrhoea.
14. Prior bariatric surgery.
15. Patients unable to undergo MRI scans (e.g. due to the individual having metallic implants).

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No